Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hwang, I. G. | - |
dc.contributor.author | Jang, J. S. | - |
dc.contributor.author | Do, J. H. | - |
dc.contributor.author | Kang, J. H. | - |
dc.contributor.author | Lee, G. W. | - |
dc.contributor.author | Oh, S. Y. | - |
dc.contributor.author | Kwon, H. C. | - |
dc.contributor.author | Jun, H. J. | - |
dc.contributor.author | Lim, H. Y. | - |
dc.contributor.author | Lee, S. | - |
dc.contributor.author | Chi, K. C. | - |
dc.contributor.author | Lee, S. J. | - |
dc.date.available | 2019-05-29T11:35:17Z | - |
dc.date.issued | 2011-10 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.issn | 1432-0843 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/21242 | - |
dc.description.abstract | Purpose The aim of this study is to evaluate the effect of excision repair cross-complementation group 1 (ERCC1) expression on treatment outcomes in advanced biliary tract adenocarcinoma (ABTA) patients treated with platinum-based chemotherapy. Methods One hundred and six patients with histologically confirmed adenocarcinoma of biliary tract were enrolled at 5 institutions in South Korea between January 2002 and September 2008. Of 106 patients, 93 were assessed by immunohistochemistry from tissue specimens. Sixty-five patients were treated with cisplatin-based regimens and the other 28 treated with oxaliplatin-based ones. Results For total study population, no significant differences were noted in progression-free survival (PFS) and overall survival (OS) between ERCC1-negative and ERCC1-positive patients, respectively (4.2 vs. 2.9 months, p = 0.116; 7.0 vs. 7.8 months, p = 0.143). In patients treated with cisplatin-based regimens, median PFS and OS were significantly longer in ERCC1-negative group than in ERCC1-positive group, respectively (4.6 vs. 1.9 months, p = 0.014; 9.1 vs. 7.9 months, p = 0.017). Disease control rate (DCR) was better in patients with ERCC1 negative than in patients with ERCC1 positive (p = 0.048). On the other hand, in patients treated with oxaliplatin-containing regimens, median PFS and OS tended to be longer in ERCC1-positive group, but these did not reach statistical significances. Response rate was better in patients with ERCC1 positive (p = 0.005). Conclusions ERCC1 shows a significant prognostic value in ABTA patients treated with cisplatin. A survival benefit was observed in ERCC1-negative patients from cisplatin-containing chemotherapy but not from oxaliplatin-containing ones. The action mechanism of ERCC1 on cisplatin may be different from that on oxaliplatin. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | SPRINGER | - |
dc.title | Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s00280-011-1558-3 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.68, no.4, pp 935 - 944 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000297122300013 | - |
dc.identifier.scopusid | 2-s2.0-80054768584 | - |
dc.citation.endPage | 944 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 935 | - |
dc.citation.title | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.volume | 68 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | Advanced biliary tract adenocarcinoma | - |
dc.subject.keywordAuthor | ERCC1 | - |
dc.subject.keywordAuthor | Cisplatin | - |
dc.subject.keywordAuthor | Oxaliplatin | - |
dc.subject.keywordPlus | MESSENGER-RNA LEVELS | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | CISPLATIN PLUS GEMCITABINE | - |
dc.subject.keywordPlus | ADVANCED GASTRIC-CANCER | - |
dc.subject.keywordPlus | THYMIDYLATE SYNTHASE | - |
dc.subject.keywordPlus | DNA-REPAIR | - |
dc.subject.keywordPlus | FLUOROURACIL CHEMOTHERAPY | - |
dc.subject.keywordPlus | COLORECTAL-CANCER | - |
dc.subject.keywordPlus | EXCISION-REPAIR | - |
dc.subject.keywordPlus | OXALIPLATIN | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.